【最新发布】WHO公布2025年南半球流感疫苗推荐组分

• an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

• an A/Croatia/10136RV/2023 (H3N2)-like virus; 

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

• an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

• an A/District of Columbia/27/2023 (H3N2)-like virus; 

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

对比2023年9月份发布的南半球流感疫苗推荐组分，今年发布的流感疫苗推荐组分主要变动如下：

WHO每年推荐流感疫苗组分对于预防流感的传播以及指导最新流感疫苗研发意义重大：

为支持季节性流感疫苗的研发，ACROBiosystems百普赛斯实时跟踪WHO最新发布，第一时间布局研发2025年南半球WHO推荐流感疫苗使用毒株相关产品，为流感疫苗研发提供有效工具，助力下一代流感疫苗的快速研发。

• 高均一性（SEC-MALS）

The purity of Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) is more than 90% and the molecular weight of this protein is around 220-265 kDa verified by SEC-MALS.

Immobilized Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) at 1 μg/mL (100 μL/well) can bind Human Anti-HA (H1N1) antibody3E1 with a linear range of 1-31.25 ng/mL (QC tested).

点击申请Protocol

• 点击下载Application Note，获取流感疫苗评价指南

参考文献

[1] Yu Y , Tazeem T , Xu Z ,et al.Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus[J].MedChemComm, 2019.DOI:10.1039/C8MD00474A.

[2] Tokars J I , Olsen S J , Reed C .Seasonal Incidence of Symptomatic Influenza in the United States[J].Clinical Infectious Diseases, 2017.DOI:10.1093/cid/cix1060.

[3] Ali S T, Cowling B J. Influenza Virus: Tracking, Predicting, and Forecasting[J]. Annual Review of Public Health, 2021, 42(1): 43-57.